Objective：This study aims to investigate whether Zinc finger protein 692（ZNF692）can be used as an independent predictor of poor prognosis in patients with gastric cancer. Methods：Immunohistochemical（IHC）staining was used to detect the expression of ZNF692 in gastric cancer tissues and adjacent tissues of 191 cases. Results：The expression of ZNF692 in gastric cancer tissues was significantly higher than that in adjacent tissues. There was no significant difference in the clinicopathological features between patients with high ZNF692 expression and those with low ZNF692 expression（P > 0.05）. However，overall survival（OS）of patients with ZNF692 high expression was significantly shorter than that of patients with ZNF692 low expression（P=0.000 1）. The mean survival time of patients with ZNF692 high expression（30.1 months）was significantly shorter than that of patients with ZNF692 low expression（42.6 months）（P < 0.01）. Cox multivariate risk regression model analysis showed that ZNF692 could be used as an independent predictor of poor prognosis in patients with gastric cancer. Conclusion：High expression of ZNF692 is one of poor prognosis predictors in patients with gastric cancer.